Article
GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Cancer letters - 28 Jun 2016
Liu Jingjing, Prager-van der Smissen Wendy J C, Look Maxime P, Sieuwerts Anieta M, Smid Marcel, Meijer-van Gelder Marion E, Foekens John A, Hollestelle Antoinette, Martens John W M
Abstract excerpt
In breast cancer, GATA3 mutations have been associated with a favorable prognosis and the response to neoadjuvant aromatase inhibitor treatment. Therefore, we investigated whether GATA3 mutations predict the outcome of tamoxifen treatment in the advanced setting. In a retrospective study consisting of 235 hormone-naive patients with ER-positive breast cancer who received tamoxifen as first-line treatment for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.